Is it safe to hypofractionate for whole breast RT in patients with a BRCA 1/2 or CHEK2 mutation to chose to have breast conservation for early stage breast cancer or DCIS?  

There is no evidence that hypofractionation compared to conventional fractionation results in higher acute or long term toxicities in patients who have these mutations. Since a majority of these patients may also be in a younger age group many clinicians may appropriately feel uncomfortable in offer...

I agree with @Bruce G. Haffty about the lack of evidence of increased toxicity in patients with BRCA1/2 or CHEK2 alterations (or PALB2 etc) and frequently refer to his important work in this area. In START B there were 108 women <= 39 and 457 women <= 49 randomized. One of the most striki...